Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Tissue Protrusion after DES: Adverse Events at Long Term?

Original Title: Tissue Protrusion after Stent Implantation. An ADAPT-DES Intravascular Ultrasound Substudy.

Reference: Fuyu Qiu et al. J Am Coll Cardiol Intv. 2016;9(14):1499-1507.

 

DESAfter DES implantation we may observe tissue protrusion (plaque or thrombus) relatively often, especially in unstable lesions; however, its clinical impact has not been studied. The aim of this study was to assess long term prevalence and clinical impact of tissue protrusion after DES implantation.

The ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) prospectively included 8,663 patients undergoing DES stenting.

In a pre-specified intravascular ultrasound (IVUS) substudy, 2,072 patients had post stenting IVUS and were classified according to presence or absence of post stenting tissue protrusion.

After stenting, 34.3% of lesions showed tissue protrusion by IVUS. Maximum tissue protrusion was 0.7 mm2 in area (range 0.5 to 1.2 mm) and 3 mm in length (range 1.4 to 6.7 mm).

Patients with tissue protrusion were often undergoing high risk ACS (STEMI and NSTEMI) and less often unstable angina or stable ischemic cardiomyopathy.

In 893 lesions studied by IVUS prior stenting, tissue protrusion was associated with larger proximal reference lumen area, greater plaque burden, and more plaque ruptures, attenuated plaque, and VH-thin cap fibroatheromas.

Because tissue protrusion often lead to post-dilation, these patients had a larger lumen area than patients without tissue protrusion.

At two year follow up, there was less clinically driven target lesion revascularization in patients with tissue protrusion and no significant difference in incidence of major adverse cardiac events (cardiac death, MI, or stent thrombosis) in patients with vs without tissue protrusion.

Conclusion

Tissue protrusion diagnosed by IVUS after DES stenting is not associated to adverse events in the long term, partly because of greater post dilation stent expansion.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...

EuroPCR 2026 | Is localized anticoagulation the next step for coronary stents?

The DESyne BDS Plus stent was developed as a thin-strut, bioabsorbable polymer drug-eluting stent that combines sirolimus release with two anticoagulant agents (rivaroxaban and...

EuroPCR 2026 | Restoring vascular physiology: 4-year results of the BIOADAPTOR-RCT

Despite advances in drug-eluting stents, device-related events continue to increase beyond the first year after angioplasty. In this context, the DynamX system emerged as...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...